News

Protein Sciences (PSC) has started manufacturing vaccine against the H1N1(Swine flu) virus. The company has estimated to produce 100,000 doses this week, and will continue with the same

MDS Nordion has announced that the company and the Karpov Institute have agreed to combine their respective expertise and resources to explore the development of a commercialization plan,

California-based, Proteolix has announced that selective immunoproteasome inhibitor PR-957 was shown to block disease progression in rheumatoid arthritis in a dose dependent manner, and completely eliminate visible signs

Sinovac, China-based developer and provider of vaccines, has declared that it has completed the construction of the H1N1 virus seed bank necessary to produce a virus antigen. Sinovac

Eli Lilly has announced that it will be initiating drug discovery in new and unmet diseases, which includes Alzheimer’s disease, Cancer, Diabetes and Osteoporosis. The company’s goal is

GlaxoSmithKline has signed an agreement with Dr. Reddy’s to develop and market selected products across an extensive number of emerging markets, excluding India. Under the terms of the

Canada-based AEterna has reported that patient follow-up in the safety study of its phase-III program in benign prostatic hyperplasia (BPH) with its endocrinology compound, cetrorelix pamoate, is scheduled

Boehringer Ingelheim and Vitae have announced that they have entered into a worldwide collaboration to research and develop beta-secretase (BACE) inhibitors, for the treatment of Alzheimer’s disease. Under

Synta, a biopharmaceutical company and GlaxoSmithKline have decided to end the collaborative agreement for the clinical development and commercialization of elesclomol, effective no later than September 10, 2009.